KRYS
Krystal Biotech, Inc. NASDAQ$286.95
Mkt Cap $8.4B
52w Low $122.80
93.5% of range
52w High $298.30
50d MA $261.82
200d MA $217.73
P/E (TTM)
37.6x
EV/EBITDA
39.6x
P/B
6.3x
Debt/Equity
0.0x
ROE
16.8%
P/FCF
37.8x
RSI (14)
—
ATR (14)
—
Beta
0.54
50d MA
$261.82
200d MA
$217.73
Avg Volume
283.4K
About
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treati…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | TNS | 1.45 | 1.83 | +26.2% | — | — | — | — | — | — | — | — | — |
| Feb 17, 2026 | TNS | 1.62 | 1.70 | +4.9% | 287.84 | -0.4% | -1.6% | -8.7% | -9.0% | -4.6% | -7.3% | -10.4% | — |
| Nov 3, 2025 | TNS | 1.12 | 2.66 | +137.5% | 197.85 | +0.0% | +2.7% | +1.0% | +1.1% | +0.0% | +0.8% | +9.9% | — |
| Aug 4, 2025 | TNS | 1.08 | 1.29 | +19.4% | 134.94 | +0.4% | +1.8% | +0.8% | +0.9% | +2.8% | +1.9% | +11.3% | — |
| May 6, 2025 | TNS | 1.38 | 1.20 | -13.0% | 139.47 | +0.8% | -1.9% | -1.6% | -5.2% | -0.0% | -3.5% | -4.9% | — |
| Feb 19, 2025 | TNS | 1.29 | 1.52 | +17.8% | 176.17 | +4.7% | +3.7% | +6.6% | +6.1% | +2.8% | +0.1% | +6.2% | — |
| Nov 4, 2024 | TNS | 0.90 | 0.91 | +1.1% | 170.85 | +1.0% | +2.1% | +7.2% | +8.5% | +16.8% | +14.6% | +9.8% | — |
| Aug 5, 2024 | TNS | 0.50 | 0.86 | +72.0% | 180.71 | +0.9% | -1.2% | -3.3% | -0.2% | +0.8% | +2.0% | +2.9% | — |
| May 6, 2024 | TNS | 0.15 | 0.03 | -80.0% | 156.94 | -0.2% | +3.1% | +0.5% | +1.1% | -1.4% | -1.4% | +6.8% | — |
| Feb 26, 2024 | TNS | -0.38 | 0.30 | +178.9% | 157.00 | +1.9% | +8.4% | +3.9% | +1.6% | +6.9% | +1.9% | +12.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | Guggenheim | Maintains | Buy → Buy | — | $266.90 | $266.90 | +0.0% | +2.1% | +3.5% | +3.3% | -3.0% | -1.2% |
| Feb 18 | Citigroup | Maintains | Buy → Buy | — | $287.84 | $286.67 | -0.4% | -1.6% | -8.7% | -9.0% | -4.6% | -7.3% |
| Feb 18 | Chardan Capital | Maintains | Buy → Buy | — | $287.84 | $286.67 | -0.4% | -1.6% | -8.7% | -9.0% | -4.6% | -7.3% |
| Feb 17 | Jefferies | Maintains | Buy → Buy | — | $276.45 | $289.00 | +4.5% | +4.1% | +2.5% | -5.0% | -5.3% | -0.7% |
| Feb 2 | Goldman Sachs | Maintains | Buy → Buy | — | $279.24 | $276.58 | -1.0% | +1.1% | +0.1% | -3.6% | -4.2% | -2.3% |
| Jan 22 | BofA Securities | Maintains | Buy → Buy | — | $286.00 | $286.20 | +0.1% | +1.1% | -1.6% | -2.5% | -3.0% | -4.6% |
| Jan 12 | Citigroup | Maintains | Buy → Buy | — | $261.41 | $260.64 | -0.3% | +4.1% | +11.7% | +11.6% | +7.9% | +9.0% |
| Jan 9 | TD Cowen | Maintains | Buy → Buy | — | $248.91 | $254.51 | +2.2% | +5.0% | +9.3% | +17.3% | +17.2% | +13.3% |
| Jan 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $248.91 | $254.51 | +2.2% | +5.0% | +9.3% | +17.3% | +17.2% | +13.3% |
| Jan 9 | Citigroup | Maintains | Buy → Buy | — | $248.91 | $254.51 | +2.2% | +5.0% | +9.3% | +17.3% | +17.2% | +13.3% |
Recent Filings
8-K · 2.02
!! High
Krystal Biotech, Inc. -- 8-K 2.02: Earnings Results
Krystal Biotech disclosed Q1 2026 financial results on May 4, 2026, showing its operational performance and financial condition for the quarter ending March 31, 2026.
May 4
8-K
Krystal Biotech, Inc. -- 8-K Filing
Krystal Biotech delivered robust 2025 results with $730.3 million in VYJUVEK revenue while advancing its pipeline through FDA's RMAT designation for KB707 in lung cancer and Fast Track status for KB111 in heart disease.
Feb 17
Data updated apr 25, 2026 6:05pm
· Source: massive.com